- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04789733
The GUARDIAN Pilot Trial (GUARDIAN)
Tight Perioperative Blood Pressure Management to Reduce Serious Cardiovascular, Renal, and Cognitive Complications: The GUARDIAN Pilot Trial
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Consenting patients who take either angiotensin converting enzyme inhibitors (ACEIs), angiotensin receptor blockers (ARBs), or calcium channel blockers will be asked not to take the medications on the morning of surgery, and instead bring them with them to the hospital. Qualifying patients will be randomized 1:1, with random-sized blocks.
Randomization will be implemented by clinicians in collaboration with research personnel. Arterial catheter transducers will be positioned at the level of the right atrium, and adjusted as necessary if patient position is changed.
The treatments will be: 1) norepinephrine or phenylephrine infusion to maintain intraoperative MAP ≥85 mmHg, delayed resumption of chronic antihypertensive medications, and a target ward MAP ≥80 mmHg (tight pressure management); or, 2) routine intraoperative blood pressure management and prompt resumption of chronic antihypertensive medications (routine pressure management).
Tight pressure management: In patients assigned to tight pressure management, angiotensin converting enzyme inhibitors and angiotensin receptor blockers will not be given the morning of surgery. Other chronic antihypertensives will only be given as necessary to treat hypertension. Clinicians will be encouraged to insert the required arterial catheter before anesthetic induction because much hypotension occurs shortly after anesthetic induction.
A norepinephrine or phenylephrine infusion (in the preferred local concentration) will be prepared, connected to an intravenous catheter, and activated at a low rate. Norepinephrine can be safely given through a central catheter or peripherally.
General anesthesia will be induced with propofol or etomidate which will be given in repeated small boluses or target-controlled infusion in an effort to keep mean arterial pressure ≥85 mmHg. Clinicians will be encouraged to use etomidate when rapid-sequence inductions are required. Simultaneously, the vasopressor infusion will be adjusted with the same goal. Anesthetic dose, fluid administration, and vasopressor administration will be adjusted with the goal of maintaining the individual designated baseline mean arterial pressure. Invasive or non-invasive advanced hemodynamic monitoring is not required, but should be used when practical. Clinicians should use available information to optimize vascular volume, afterload, and inotropy.
Resumption of chronic anti-hypertensive medications will be delayed until the third postoperative day unless deemed necessary to treat hypertension or for some other clear indication (e.g., preventing atrial fibrillation in a chronic beta-blocker user) because >90% of MINS occurs within 48 hours after surgery. When necessary to treat hypertension, chronic antihypertensive or new medications can be used per clinician preference. Clinicians will make what efforts they can to maintain postoperative mean arterial pressures ≥80 mmHg during the initial three postoperative days by maintaining adequate hydration, using inotropic and chronotropic drugs, and vasopressor as necessary. This protocol specifies the blood pressure target but leaves implementation to clinical judgement.
Routine pressure management: In patients assigned to routine pressure management, ACEIs, ARBs, and/or calcium channel blockers can be given the morning of surgery if deemed appropriate by the attending anesthesiologist. The arterial catheter will be inserted before or after induction of anesthesia per clinician preference. General anesthesia will be induced and maintained per routine. Blood pressure will not be deliberately reduced, but per routine clinicians will presumably not intervene until MAP is <65 mmHg. As usual, chronic anti-hypertensive medications will be restarted shortly after surgery unless contraindicated by hypotension.
In both groups, other aspects of anesthetic management will be at the discretion of the responsible anesthesiologist, including the types and volumes of various fluids. Volatile or intravenous anesthesia is permitted.
There will be no limitation on ancillary vasoactive, chronotropic, and inotropic drugs. Clinicians will be free to use advanced hemodynamic monitoring (e.g., pulse-wave analysis, esophageal Doppler, etc.). Blood products will be given per routine. Similarly, postoperative analgesic management will be per routine and clinician preference. Neuraxial and peripheral nerve blocks are permitted, but epidural catheters should not be activated until surgery is nearly finished.
Because patients must be fairly sick to qualify for GUARDIAN, some will go to directly from surgery to critical care units, or much less often, become unstable and require transfer from a routine ward to an ICU. In either case, every effort will be to maintain randomized treatments and blood pressure targets.
In all cases, good judgement will predominate. Clinicians should always act in their patients' best interests, irrespective of the GUARDIAN protocol
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Roberta Johnson
- Phone Number: 216-444-9950
- Email: johnsor13@ccf.org
Study Locations
-
-
Jilin
-
Changchun, Jilin, China
- Recruiting
- China Japan Union Hospital of Jilin University
-
Contact:
- Kai Li, MD
- Phone Number: +86-0431-89876725
- Email: likai@jlu.edu.cn
-
Principal Investigator:
- Kai Li, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- ≥45 years old
- Scheduled for major noncardiac surgery expected to last at least 2 hours;
- Having general endotracheal, neuraxial anesthesia, or the combination;
- Expected to require at least overnight hospitalization;
- Are designated ASA physical status 2-4 (ranging from mild systemic disease through severe systemic disease that is a constant threat to life);
- Chronically taking at least one anti-hypertensive medication;
- Expected to have direct blood pressure monitoring with an arterial catheter;
- Cared for by clinicians willing to follow the GUARDIAN protocol;
- Subject to at least one of the following risk factors:
- History of peripheral arterial surgery;
- History of coronary artery disease;
- History of stroke or transient ischemic attack;
- Serum creatinine >175 µmol/L (>2.0 mg/dl);
- Diabetes requiring medication;
- Current smoking or 15 pack-year history of smoking tobacco;
- Scheduled for major vascular surgery;
- Body mass index ≥35 kg/m2;
- Preoperative high-sensitivity troponin T >14 ng/L or troponin I equivalent;
- B-type natriuretic protein (BNP) >80 ng/L or N-terminal B-type natriuretic protein (NT-ProBNP) >100 ng/L
Exclusion Criteria:
- Are scheduled for carotid artery surgery;
- Are scheduled for intracranial surgery;
- Are scheduled for partial or complete nephrectomy;
- Are scheduled for pheochromocytoma surgery;
- Are scheduled for liver transplantation;
- Require preoperative intravenous vasoactive medications;
- Have a condition that precludes routine or tight blood pressure management such as surgeon request for relative hypotension;
- Require beach-chair positioning;
- Have end-stage renal disease requiring dialysis or estimated glomerular filtration rate (eGFR) <30 ml/min;
- Have a documented history of dementia;
- Have language, vision, or hearing impairments that may compromise cognitive assessments;
- Have contraindications to norepinephrine or phenylephrine per clinician judgement;
- Have previously participated in this trial.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Routine pressure management
ACEIs, ARBs, and/or calcium channel blockers can be given the morning of surgery if deemed appropriate by the attending anesthesiologist.
Intraoperative blood pressure will be managed per clinical routine.
As usual, chronic anti-hypertensive medications will be restarted shortly after surgery unless contraindicated by hypotension.
|
Routine intraoperative blood pressure management and immediate restart of antihypertensive medications.
|
Experimental: Tight pressure management
Patients assigned to tight blood pressure control angiotensin converting enzyme inhibitors and angiotensin receptor blockers will not be given the morning of surgery. Other chronic antihypertensives will only be given as necessary to treat hypertension. Norepinephrine or phenylephrine infusion will be infused at a rate sufficient to maintain intraoperative MAP ≥ 85 mmHg. Resumption of chronic anti-hypertensive medications will be delayed until the third postoperative day unless deemed necessary to treat hypertension or for some other clear indication. The target for postoperative systolic arterial pressures ≥110 mmHg during the initial three postoperative days. |
Norepinephrine or phenylephrine infusion to maintain intraoperative MAP ≥85 mmHg, delayed resumption of chronic antihypertensive medications, and a target ward MAP ≥80 mmHg (tight pressure management)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intraoperative blood pressure management
Time Frame: Intraoperative
|
The fraction of time when intraoperative MAP is <65 mmHg and ≥85 mmHg during surgery.
|
Intraoperative
|
Postoperative blood pressure management
Time Frame: First 3 postoperative days
|
Time to restarting routine antihypertensive medications.
|
First 3 postoperative days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intraoperative pressure
Time Frame: Intraoperative
|
Time-weighted mean-arterial pressure
|
Intraoperative
|
Postoperative pressure
Time Frame: Initial 3 postoperative days
|
Time-weighted systolic pressure
|
Initial 3 postoperative days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Perfusion-related complications
Time Frame: 30 days
|
A composite of serious perfusion-related complications: myocardial injury, stroke, non-fatal cardiac arrest, Stage 2-3 acute kidney injury, deep or organ-space infection, sepsis, and death.
|
30 days
|
Delirium
Time Frame: Initial 4 postoperative days
|
Postoperative delirium assessed with 3D CAM ICU twice daily.
|
Initial 4 postoperative days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- The GUARDIAN pilot trial
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on General Surgery
-
The Cleveland ClinicCompletedLaparoscopic Surgery | Surgery | General Anesthesia | PostoperativeUnited States
-
McGill University Health Centre/Research Institute...Society of American Gastrointestinal and Endoscopic SurgeonsCompletedBreast Surgery | Abdominal Surgery | Outpatient SurgeryCanada
-
Sun Yat-sen UniversityCompletedRobotic Surgery | General Anesthesia | Mechanical Ventilation | Urological SurgeryChina
-
3MRecruitingAbdominal Surgery | Orthopedic Surgery | Vascular Surgery | Cardiovascular SurgeryUnited States
-
Vanderbilt UniversityCompletedHand Surgery | Wrist Surgery | Forearm Surgery | Elbow SurgeryUnited States
-
Huazhong University of Science and TechnologyCompletedLaparoscopic Surgery | Hysteroscopic SurgeryChina
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, WisconsinCompletedAbdominal Surgery | Thoracic SurgeryUnited States
-
University Hospital, MontpellierUnknownHand Surgery | Wrist SurgeryFrance
-
Nantes University HospitalCompletedGynecological Surgery | Plastic Surgery | ENT SurgeryFrance
-
Mayo ClinicWithdrawnGeneral SurgeryUnited States
Clinical Trials on Tight pressure management
-
Miodrag Filipovic, Prof. Dr. med.CompletedHeart Failure | Stroke | Postoperative Complications | Renal Insufficiency, Chronic | Death | Acute Coronary Syndrome | Acute Kidney Injury | Hypotension | Coronary OcclusionSwitzerland
-
Women and Infants Hospital of Rhode IslandCompletedGestational Diabetes MellitusUnited States
-
Alisse HauspurgRecruitingCardiovascular Diseases | Vascular Diseases | Toxemia | Hypertension | Pregnancy Complications | Eclampsia | Pre-Eclampsia | Hypertensive Disorder of Pregnancy | Gestational Hypertension | Hypertension, Pregnancy Induced | Hypertension;Pre-EclampticUnited States
-
Rutgers, The State University of New JerseyCompleted
-
Nanfang Hospital of Southern Medical UniversityHenan Provincial People's Hospital; Xinqiao Hospital of ChongqingActive, not recruitingCardiovascular ComplicationChina
-
Seoul National University HospitalCompletedBlood Pressure | Perioperative Myocardial Injury | Non-cardiac SurgeryKorea, Republic of
-
Cairo UniversityCompletedOrthopedic Disorder | Orthopedic Devices Associated With Misadventures
-
American Pharmacists Association FoundationCompletedCardiovascular Diseases | Hypertension | Blood PressureUnited States
-
Julia BrownPfizer; Arthritis Research UKCompleted
-
Assiut UniversityCompleted